Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03998436
Other study ID # NG-A16
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 26, 2018
Est. completion date December 6, 2021

Study information

Verified date August 2023
Source Novalead Pharma Private Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the current Study is to determine the safety and effectiveness of Galnobax® plus Standard of Care versus only Standard of Care, in treating Diabetic Foot Ulcers (DFU). In addition, Study is designed to investigate the safety of Galnobax® vehicle for establishing non-deleterious effects of Vehicle on wound healing in the Subjects with DFU. The study is being conducted in 350 subjects being recruited in about 30 centers in India.


Description:

The current study is a Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (Galnobax®) in Treating Diabetic Foot Ulcers. The study evaluates the safety and effectiveness of Galnobax® plus Standard of Care versus only Standard of Care, in treating Diabetic Foot Ulcers (DFU). In addition, Study is designed to investigate the safety of Galnobax® vehicle for establishing non-deleterious effects of Vehicle on wound healing in the Subjects with DFU.


Recruitment information / eligibility

Status Completed
Enrollment 176
Est. completion date December 6, 2021
Est. primary completion date August 19, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Subjects, male or female, aged 18 to 75 years (inclusive) with Type 1 or Type 2 diabetes undergoing therapy for glycemic control 2. Subject has glycosylated hemoglobin, HbA1C, = 12% 3. Subject with diagnosis of neuropathic foot ulcer by 10g monofilament test 4. Subject has adequate vascular perfusion of the affected limb, confirmed by Ankle-Brachial Index (ABI) = 0.65 and = 1.3 5. Presence of at least one DFU that meets all of the following criteria: 1. A full-thickness ulcer of Grade A1 as per Texas classification system; 2. Ulcer is located below or up to 5 cm above the malleoli (excluding ulcers between the toes); 3. Ulcer size (area) is = 2 cm2 and = 15 cm2 (post-debridement); 4. There is a minimum 3 cm margin between the qualifying Target Ulcer and any other ulcers on the specified foot, post-debridement; 5. No exposed bone, tendon, muscle, ligament or joint capsule, and no tunneling, undermining, or sinus tracts; 6. Unresponsive to ulcer care and open for at least 6 weeks at the time of the Screening Visit; 7. Ulcer is non-infected as determined by clinical assessment and complete hemogram; 8. Ulcer has a clean, granulating base free of adherent slough to the greatest extent possible as per Investigator; 9. Ulcer area reduction < 30% from the Screening Visit to Baseline visit 6. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Investigator 7. Subject, if female of child-bearing potential, has a negative urine pregnancy test at Screening and willing to use acceptable methods of contraception (birth control pills, barriers) or abstinence throughout the Study 8. Subject is able and willing to comply with Study procedures including the use of an off-loading device (as applicable for the location of the ulcer) and adhere to protocol during the Study in the opinion of Investigator 9. A Subject or LAR agrees to sign informed consent form and allow audio visual recording of consent, if applicable Exclusion Criteria: 1. Actively infected ulcers with or without purulent discharge, ulcers with exposed bone or associated with osteomyelitis 2. Subjects with more than three ulcers below knee 3. Subjects with Target Ulcer requiring off-loading that cannot be effectively off-loaded; or unable to tolerate the off-loading method 4. Subject has ulcers caused by a disease other than diabetes, e.g., fungal ulcerations, malignant ulcerations, and ulcerations due to venous or arterial insufficiency, or due to hematological disorders, in the opinion of the Investigator 5. Ulcer, about which the Investigator is suspicious for cancer 6. Subjects with a gangrenous or ischemic ulcer 7. Subject with ulcer that in the opinion of the Investigator, may need amputation 8. Subject with Target ulcer where wound measurement is not possible, such as ulcers between toes 9. Body mass index (BMI) > 40 kg/m2 10. Laboratory values at Screening of: 1. Hemoglobin < 10.0 g/dL 2. White Blood Cells (WBC) < 2.0 X 109 cells/L 3. Liver function studies [Total bilirubin, aspartate aminotransferase (AST) and alanine transaminase (ALT)] > 3x the upper limit of normal 4. Albumin < 2.5 g/dL 5. eGFR < 25 mL/min 11. Presence of any existing clinically significant medical condition(s) that, in the opinion of the Investigator, could interfere with wound healing 12. Subject has received or is currently receiving or scheduled to receive any medication or therapies during the course of the Study that will modulate wound healing 13. Subject with intolerance to ß-blockers at any time in the past 14. Has any other factor which may, in the opinion of the Investigator, compromise participation and/or follow-up in the Study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Esmolol Hydrochloride
Galnobax-14% gel application along with Standard of Care
Other:
Only Standard of Care
Only Standard of Care treatment
Vehicle Gel
Vehicle gel application along with Standard of Care

Locations

Country Name City State
India M.S. Ramaiah Medical College and Hospital Bangalore Karnataka
India Rajlaxmi Hospital Bangalore Karnataka
India Sapthagiri Institute of Medical Sciences and Research Centre Bangalore Karnataka
India Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh
India Appollo Hospital Chennai Tamilnadu
India M.V. Hospital for Diabetes Pvt Ltd Chennai Tamilnadu
India Madras Diabetes Research Foundation Chennai Tamilnadu
India Sri Ramachandra Hospital Chennai Tamilnadu
India Sujata Birla Hospital & Medical Research Center Nashik Maharashtra
India Maharaja Agrasen Hospital New Delhi
India Chellaram Diabetes Institute Pune Maharashtra
India Deenanath Mangeshkar Hospital and Research Center Pune Maharashtra
India Sri Siddhartha Medical College Tumkur Karnataka
India Yalamanchi Hospita Vijayawada Andhra Pradesh

Sponsors (1)

Lead Sponsor Collaborator
Novalead Pharma Private Limited

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Other Proportion of Subjects With Treatment Emergent Adverse Events (TEAEs) Proportion of Treatment emergent adverse events (TEAEs) in all the groups 24-weeks
Primary Proportion of Subjects Achieving Target Ulcer Closure Within 12-week Treatment Phase, as Assessed by Blinded Investigator Proportion of complete closure of wounds within 12-week treatment phase where Complete wound closure is defined as complete skin re-epithelialization that is without drainage or dressing requirements evaluated in two visits two weeks apart from first observation of closure. Wound closure assessed up to week 12 and confirmed by 2 visits 2 weeks apart; only participants with wound closure at or before Week 12 and who maintained closure after 4-weeks of follow-up reported
Secondary Proportion of Subjects Achieving Target Ulcer Closure Till End of Study, as Assessed by the Blinded Investigator. Proportion of complete closure of wounds at 24-weeks or End of Study where Complete wound closure is defined as complete skin re-epithelialization that is without drainage or dressing requirements. 24-weeks. The ulcers achieving complete closure till end of study
See also
  Status Clinical Trial Phase
Recruiting NCT04497805 - Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers Phase 2
Withdrawn NCT03675269 - Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer: N/A
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06439667 - VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
Recruiting NCT05608187 - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers Phase 2
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Not yet recruiting NCT06437028 - Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers. N/A
Withdrawn NCT05024656 - AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers N/A
Terminated NCT02202668 - Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers N/A
Terminated NCT01966380 - Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Phase 2
Completed NCT01951768 - Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Phase 4
Completed NCT01657474 - Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers N/A
Active, not recruiting NCT00389636 - TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers N/A
Completed NCT01181440 - Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers Phase 3
Enrolling by invitation NCT05888259 - Plantar Pressure Distribution in Diabetic Foot Ulcer N/A
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Not yet recruiting NCT05877378 - Efficacy of PICO Single-use System in Chronic Ulcers N/A
Recruiting NCT06037369 - The Short Message-based Customized Standardized N/A
Completed NCT03312595 - Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) N/A
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A